Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities

Rashidi, Niloufar; Davidson, Majid; Apostolopoulos, Vasso; Nurgali, Kulmira

doi:10.1016/j.jddst.2024.105599

Cited by 2 publications

(1 citation statement)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, there has been a growing search for developing high-efficiency nanomedicines for cancer treatment [1][2][3][4]. Consequently, the scientific community has focused on improving the targeting of nanoparticles (NPs) to tumor cells through surface functionalization with active groups (e.g., folate, monoclonal antibodies, etc.)…”

Section: Introductionmentioning

confidence: 99%

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids

Sousa Ribeiro,

da Silva,

Domingues

et al. 2024

Preprint

View full text Add to dashboard Cite

Most commercial anti-cancer nanomedicines are administered intravenously. This route is fast and precise as the drug enters directly into the systemic circulation, without undergoing absorption processes. When nanoparticles come into direct contact with the blood, however, they interact with physiological components that can induce colloidal destabilization and/or changes in their original biochemical identity, compromising their ability to selectively accumulate at target sites. In this way, these systems usually lack active targeting, offering limited therapeutic effectiveness. In the literature, there is a paucity of in-depth studies in complex environments to evaluate nanoparticle stability, protein corona formation, hemolytic activity, and targeting capabilities. To address this issue, fluorescent silica nanoparticles (SiO2NPs) are here functionalized with zwitterionic (kinetic stabilizer) and folate groups (targeting agent) to provide selective interaction with tumor cell lines in biological media. The stability of these dually functionalized SiO2NPs is preserved in unprocessed human plasma while yielding a decrease in the number of adsorbed proteins. Experiments in rat blood further proved that these nanoparticles are not hemolytic. Remarkably, the functionalized SiO2NPs are more internalized by tumor cells than their healthy counterparts. Investigations of this nature play a crucial role in garnering results with greater reliability, allowing the development of nanoparticle-based pharmaceutical drugs that exhibit heightened efficacy and reduced toxicity for medical purposes.

show abstract

Section: Introductionmentioning

confidence: 99%

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids

Sousa Ribeiro,

da Silva,

Domingues

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer

Oehler,

Rajapaksha,

Albrecht

2024

JPM

View full text Add to dashboard Cite

Breast cancer remains the most prevalent cancer among women worldwide, driving the urgent need for innovative approaches to diagnosis and treatment. This review highlights the pivotal role of nanoparticles in revolutionizing breast cancer management through advancements of interconnected approaches including targeted therapy, imaging, and personalized medicine. Nanoparticles, with their unique physicochemical properties, have shown significant promise in addressing current treatment limitations such as drug resistance and nonspecific systemic distribution. Applications range from enhancing drug delivery systems for targeted and sustained release to developing innovative diagnostic tools for early and precise detection of metastases. Moreover, the integration of nanoparticles into photothermal therapy and their synergistic use with existing treatments, such as immunotherapy, illustrate their transformative potential in cancer care. However, the journey towards clinical adoption is fraught with challenges, including the chemical feasibility, biodistribution, efficacy, safety concerns, scalability, and regulatory hurdles. This review delves into the current state of nanoparticle research, their applications in breast cancer therapy and diagnosis, and the obstacles that must be overcome for clinical integration.

show abstract

Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities

Cited by 2 publications

References 221 publications

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer

Contact Info

Product

Resources

About

Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities

Cited by 2 publications

References 221 publications

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO2NPs in Complex Biological Fluids

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO2NPs in Complex Biological Fluids

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer

Contact Info

Product

Resources

About

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids

Dual-Functionalized Architecture Enables Stable and Tumor Cell-Specific SiO₂NPs in Complex Biological Fluids